High-dose etoposide treatment for CNS involvement in a patient with primary non-Hodgkin's lymphoma of the breast

Internal Medicine

Volumn 36, Issue 10, 1997, Pages 738-741

  Kohara, Hiroyuki ^a   Ueoka, Hiroshi ^a   Tabata, Masahiro ^a   Shinagawa, Katsuji ^a   Hayashi, Kyoichi ^b   Harada, Mine ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Okayama Red Cross Hospital   (Japan)

Author keywords

Breast lymphoma; Central nervous system (CNS) lymphoma; High dose etoposide

Indexed keywords

ETOPOSIDE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CASE REPORT; DRUG EFFICACY; HUMAN; MALE; NONHODGKIN LYMPHOMA;

EID: 0030670782     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.36.738     Document Type: Article

References (12)

1. Liang RH, Woo EK, Yu YL, et al. Central nervous system involvement in non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol 25: 703, 1989.
2. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer 74: 1383, 1994.
3. Wisemann C, Liao KT. Primary lymphoma of the breast. Cancer 29: 1705, 1972.
4. Hugh JC, Jackson FI, Hanson J, Poppema S. Primary Breast Lymphoma. An immunohistologic study of 20 new cases. Cancer 66: 2602, 1990.
5. Recht L, Straus DJ, Cirrincione C, Thaler HT, Posner JB. Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis. Am J Med 84: 425, 1988.
6. Creaven PJ. The clinical pharmacology of VM 26 and VP 16-213. A brief overview. Cancer Chemother Pharmacol 7: 133, 1982.
7. Postmus PE, Holthuis JJ, Haaxma-Reiche H, et al. Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration. J Clin Oncol 2: 215, 1984.
8. Kiya K, Uozumi T, Ogasawara H, et al. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer Chemother Pharmacol 29: 339, 1992.
9. Postmus PE, Haaxma-Reiche H, Sleijfer DT, Kirkpatrick A, McVie JG, Kleisbauer JP, and The EORTC Lung Cancer Cooperative Group. High-dose etoposide for brain metastases of small cell lung cancer. A phase II study. Br J Cancer 59: 254, 1989.
10. Copelan EA, Ceselski SK, Ezzone SA, et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol 15: 759, 1997.
11. Vose JM, Andersen JR, Kessinger A, et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma (see comments). J Clin Oncol 11: 1846, 1993.
12. Postmus PE, Haaxma-Reiche H, Berendsen HH, Sleijfer DT. High-dose etoposide for meningeal carcinomatosis in patients with small cell lung cancer. Eur J Cancer Clin Oncol 25: 377, 1989.